Virtu Financial LLC Purchases New Stake in Adicet Bio, Inc. (NASDAQ:ACET)

Virtu Financial LLC acquired a new position in Adicet Bio, Inc. (NASDAQ:ACET) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,611 shares of the company’s stock, valued at approximately $29,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its stake in shares of Adicet Bio by 10,321.9% in the third quarter. JPMorgan Chase & Co. now owns 80,353 shares of the company’s stock valued at $116,000 after purchasing an additional 79,582 shares during the period. FMR LLC lifted its position in shares of Adicet Bio by 31.3% during the 3rd quarter. FMR LLC now owns 276,169 shares of the company’s stock valued at $398,000 after acquiring an additional 65,903 shares during the period. XTX Topco Ltd lifted its position in shares of Adicet Bio by 12.5% during the 3rd quarter. XTX Topco Ltd now owns 292,180 shares of the company’s stock valued at $421,000 after acquiring an additional 32,392 shares during the period. RBF Capital LLC boosted its stake in shares of Adicet Bio by 62.5% during the 3rd quarter. RBF Capital LLC now owns 601,135 shares of the company’s stock worth $866,000 after acquiring an additional 231,135 shares in the last quarter. Finally, Regeneron Pharmaceuticals Inc. acquired a new stake in shares of Adicet Bio in the 4th quarter worth approximately $931,000. Institutional investors and hedge funds own 83.89% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on ACET. HC Wainwright reiterated a “neutral” rating on shares of Adicet Bio in a research report on Friday, March 7th. Guggenheim reiterated a “buy” rating and issued a $7.00 price objective on shares of Adicet Bio in a research report on Friday, March 21st. Finally, JMP Securities restated a “market perform” rating on shares of Adicet Bio in a report on Thursday, February 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $7.50.

Adicet Bio Trading Down 2.6 %

NASDAQ:ACET opened at $0.74 on Wednesday. Adicet Bio, Inc. has a 12-month low of $0.74 and a 12-month high of $2.40. The firm has a market cap of $60.77 million, a price-to-earnings ratio of -0.43 and a beta of 1.97. The company’s 50-day moving average is $0.88 and its two-hundred day moving average is $1.07.

Adicet Bio (NASDAQ:ACET) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.05. On average, equities research analysts forecast that Adicet Bio, Inc. will post -1.39 earnings per share for the current fiscal year.

Adicet Bio Company Profile

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.